When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

Results of two phase 3 studies — IMvigor011 and DYNAMIC-III — presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2025 suggest that circulating tumor DNA (ctDNA) could help ...

Bladder cancer is a common cancer and one of the most costly to treat, yet there has been little change in the standard of care in 40 years. This panel will focus on the unmet needs in bladder cancer ...

On Tuesday, Merck & Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for ...

A cancer-drug combination from Merck, Pfizer and Astellas Pharma has hit a key goal in a late-stage study in patients with a hard-to-treat form of bladder cancer. The companies on Tuesday said Merck's ...

The addition of durvalumab to bacillus Calmette-Guérin therapy significantly extended DFS for patients with high-risk non-muscle-invasive bladder cancer, according to results of a randomized phase 3 ...